Tyagarajan Seshu 4/A
4/A · Candel Therapeutics, Inc. · Filed Mar 20, 2025
Insider Transaction Report
Form 4/AAmended
Tyagarajan Seshu
Chief Technology Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-17$1.29/sh+20,000$25,800→ 116,790 total - Sale
Common Stock
2025-03-17$8.82/sh−31,278$275,947→ 85,512 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-17−20,000→ 70,000 totalExercise: $1.29Exp: 2033-04-28→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.67 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.
- [F3]This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.